Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Cerevel Therapeutics's Emraclidine?
Emraclidine is a small molecule commercialized by Cerevel Therapeutics, with a leading Phase II program in Schizophrenia. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AbbVie's Emraclidine?
Emraclidine is a small molecule commercialized by AbbVie, with a leading Phase II program in Schizophrenia. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of Cerevel Therapeutics's Emraclidine?
Emraclidine is a small molecule commercialized by Cerevel Therapeutics, with a leading Phase II program in Schizophrenia. According to Globaldata,...
Emraclidine by Cerevel Therapeutics for Dementia Associated With Alzheimer's Disease: Likelihood of Approval
Emraclidine is under clinical development by Cerevel Therapeutics and currently in Phase I for Dementia Associated With Alzheimer's Disease. According...